Antibodies News and Research

RSS

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

A recent study published in the journal of Mayo Clinic Proceedings predicted the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) natural infection in vaccinated individuals.

21 Feb 2022

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.

21 Feb 2022

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

researchers determine the strong neutralizing mucosal component emanating from intramuscular administration of an mRNA vaccine.

21 Feb 2022

SARS-CoV-2 Omicron variant prompts system sciences and precision medicine

In a new review study, researchers aimed to describe the emergence of the Omicron variant, its structure, its impact on health and health systems, and the challenges that can be expected due to this variant.

21 Feb 2022

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

21 Feb 2022

Mechanisms of IL-6 expression in peripheral monocyte-derived macrophages infected with SARS-CoV-2

Researchers examined the detailed mechanisms of ‘cytokine storm’ that induces ARDS, often resulting in the death of severely ill COVID-19 patients.

21 Feb 2022

N-glycosylation blockers reduce SARS-CoV-2 infection

A new Virology study shows that the N-glycosylation pattern of SARS-CoV-2 is crucial to normal spike activity.

20 Feb 2022

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

A new study describes a potential new approach to treating COVID-19 in the form of single-chain fragment variable (scFv) antibodies.

20 Feb 2022

Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed

A new study explains how SARS-CoV-2 adapts its immunogenicity to the immune response of the host.

20 Feb 2022

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

Researchers have developed a new vaccine candidate that is specifically targeted against the SARS-CoV-2 Omicron variant.

20 Feb 2022

T-cell responses linked with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer

T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers.

18 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

Research provides a stronger connection between autoantibody formation and clotting in COVID-19

Scientists have discovered that "rogue" antibodies found circulating in the blood of COVID-19 patients have the potential to cause cells to lose their resistance to clotting.

18 Feb 2022

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.

18 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Researchers evaluated the neutralizing capacity of the clinically approved mAbs against the SARS-CoV-2 Omicron BA.2 variant.

18 Feb 2022

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

Researchers evaluated the efficacy of an mRNA vaccine booster dose against severe acute respiratory syndrome coronavirus-2 during the Omicron surge.

18 Feb 2022

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Researchers designed an electrochemiluminescence-based serology test with remarkable sensitivity to precisely quantify the amounts of anti-RBD antibodies in individuals infected with SARS-CoV-2.

18 Feb 2022

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Researchers developed a ‘bait and capture’ system which was further followed by a multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry analyses for the comparison of immune correlates in response to vaccination, natural infection, as well as protection against SARS-CoV-2 variants.

18 Feb 2022

Study finds antigenic profile of Omicron RBD is distinct from the prior SARS-CoV-2 variants of concern

A new study aimed to clarify whether extensive RBD mutations could affect the magnitude and immunodominance hierarchy of the host antibody response.

18 Feb 2022

Antibodies News and Research

Using IgG antibody assay to Identify natural SARS-CoV-2 infection in vaccinees

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Study reports potently neutralizing mucosal IgA in saliva of BNT162b2 vaccine recipients

SARS-CoV-2 Omicron variant prompts system sciences and precision medicine

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

Mechanisms of IL-6 expression in peripheral monocyte-derived macrophages infected with SARS-CoV-2

N-glycosylation blockers reduce SARS-CoV-2 infection

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

Mechanism of fatty-acid coupled adaptive immunity in SARS-CoV-2 revealed

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

T-cell responses linked with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Research provides a stronger connection between autoantibody formation and clotting in COVID-19

Study reveals the structural, functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Study explores efficacy of mRNA vaccine booster doses during the SARS-CoV-2 Omicron wave

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

Study finds antigenic profile of Omicron RBD is distinct from the prior SARS-CoV-2 variants of concern

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News